RecruitingPhase 1Phase 2NCT04502394

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma or Relapsed/Refractory Chronic Lymphocytic Leukemia

Sponsor

Kartos Therapeutics, Inc.

Enrollment

84 participants

Start Date

Feb 23, 2021

Study Type

INTERVENTIONAL

Conditions

Diffuse Large B Cell Lymphoma Chronic Lymphocytic Leukemia Non-Hodgkin Lymphoma

Summary

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia. Participants must be relapsed/refractory (having failed prior therapy)

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called KRT-232 and a drug called acalabrutinib for people with chronic lymphocytic leukemia, diffuse large b cell lymphoma, and other related conditions. The study is currently recruiting participants at 45 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGKRT-232

KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth

DRUGacalabrutinib

acalabrutinib is a BTK inhibitor anticancer drug taken by mouth

Locations(45)

Goshen Center for Cancer Care

Goshen, Indiana, United States

University of Cincinnati

Cincinnati, Ohio, United States

The Ohio State University Comprehensive Cancer Center

Columbus, Ohio, United States

UT Southwestern Medical Center

Dallas, Texas, United States

Royal Adelaide Hospital

Adelaide, Australia

Eastern Health - Box Hill Hospital

Box Hill, Australia

Barwon Health

Geelong, Australia

Royal Perth Hospital

Perth, Australia

Antwerp University Hospital (UZA)

Edegem, Belgium

Jessa Ziekenhuis

Hasselt, Belgium

University Hospital (UZ) Leuven

Leuven, Belgium

Fakultni Nemocnice Hradec Kralove

Nový Hradec Králové, Czechia

Fakultni nemocnice Ostrava

Ostrava, Czechia

Vseobecna fakultni nemocnice v Praze

Prague, Czechia

CHU de Nantes - Hôtel-Dieu

Nantes, France

Centre Henri Becquerel

Rouen, France

CHRU de Tours - Hôpital Bretonneau

Tours, France

Centro Riferimento Oncologico - Aviano

Aviano, Italy

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

Meldola, Italy

ASST Grande Ospedale Metropolitano Niguarda

Milan, Italy

IRCCS Ospedale San Raffaele

Milan, Italy

Fondazione IRCCS Policlinico San Matteo

Pavia, Italy

Centro Ricerche Cliniche di Verona s.r.l.

Verona, Italy

Copernicus PL Sp. z o.o., Wojewodzkie Centrum Onkologii

Gdansk, Poland

Uniwersyteckie Centrum Kliniczne, Klinika Hematologii i Transplantologii

Gdansk, Poland

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Oddzial w Gliwicach - Klinika Transplantacji Szpiku i Onkohematologii

Gliwice, Poland

Pratia MCM Krakow

Krakow, Poland

Szpital Uniwersytecki Krakow - Oddzial Kliniczny Hematologii

Krakow, Poland

Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego we Wroclawiu

Wroclaw, Poland

Hospital de Braga

Braga, Portugal

Centro Hospitalar Universitario de Lisboa Norte - Hospital de Santa Maria

Lisbon, Portugal

Champalimaud Cancer Center

Lisbon, Portugal

Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE

Porto, Portugal

Centro Hospitalar de Vila Nova de Gaia/Espinho EPE

Vila Nova de Gaia, Portugal

National Cancer Center

Goyang, South Korea

Gachon University Gil Medical Center

Incheon, South Korea

Samsung Medical Center

Seoul, South Korea

Seoul National University Hospital

Seoul, South Korea

Seoul St. Mary's Hospital

Seoul, South Korea

Severance Hospital, Yonsei University Health System

Seoul, South Korea

Kantonsspital St. Gallen

Sankt Gallen, Switzerland

St James's University Hospital

Leeds, United Kingdom

King's College Hospital

London, United Kingdom

Royal Marsden Foundation Trust

London, United Kingdom

University Hospital Southampton NHS Foundation Trust

Southampton, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04502394

Related Trials

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

NCT04269902631 locations

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

NCT06717347268 locations

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

NCT0639510371 locations

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

NCT032236101 location

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

NCT05139017135 locations